GH Research (NASDAQ:GHRS) Shares Up 3.1% – Should You Buy?

GH Research PLC (NASDAQ:GHRS)’s stock price traded up 3.1% during mid-day trading on Monday . The company traded as high as $9.05 and last traded at $8.88. 18,510 shares changed hands during mid-day trading, a decline of 77% from the average session volume of 79,195 shares. The stock had previously closed at $8.61.

Analyst Ratings Changes

GHRS has been the subject of a number of research analyst reports. JMP Securities reaffirmed a “market outperform” rating and set a $39.00 price objective on shares of GH Research in a research note on Wednesday, September 4th. HC Wainwright reaffirmed a “buy” rating and set a $40.00 price target on shares of GH Research in a research report on Thursday, September 5th.

GH Research Price Performance

The stock has a 50-day simple moving average of $7.76 and a 200-day simple moving average of $10.42. The stock has a market cap of $483.86 million, a PE ratio of -13.25 and a beta of 0.74.

GH Research (NASDAQ:GHRS) last issued its earnings results on Tuesday, September 3rd. The company reported ($0.20) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.23) by $0.03. As a group, equities research analysts anticipate that GH Research PLC will post -0.85 EPS for the current year.

Institutional Investors Weigh In On GH Research

An institutional investor recently raised its position in GH Research stock. Lynx1 Capital Management LP increased its holdings in shares of GH Research PLC (NASDAQ:GHRS) by 80.1% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 3,310,563 shares of the company’s stock after purchasing an additional 1,471,946 shares during the period. GH Research accounts for about 9.1% of Lynx1 Capital Management LP’s holdings, making the stock its 6th biggest holding. Lynx1 Capital Management LP owned approximately 6.36% of GH Research worth $35,291,000 as of its most recent filing with the Securities and Exchange Commission. Hedge funds and other institutional investors own 56.90% of the company’s stock.

GH Research Company Profile

GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD).